Vivanta Industries Limited has submitted a regulatory disclosure to BSE Limited regarding an upcoming board meeting scheduled for Friday, 24th July 2026 at 04:00 P.M. at the company's registered office.
The board meeting agenda includes seven key items:
1. Consideration and approval of Unaudited Standalone and Consolidated Financial Results along with Limited Review Report for the quarter ended 30th June 2026.
2. Authorization of signatories for signing the Financial Statements for the financial year ended 31st March 2026.
3. Note of issuance of Duplicate Share Certificate(s) in lieu of original share certificate(s) reported as lost/misplaced by shareholders.
4. Note of certain business collaboration agreements with Qness Pharmaceuticals, a proprietorship concern, regarding the manufacture, supply, branding and marketing of pharmaceutical and allied products.
5. Note of Corporate Governance Report for the quarter ended 30th June 2026.
6. Note of E-Form DPT-3 Return of Deposits for the quarter ended 30th June 2026.
7. Any other business with the permission of the Chair.
The notice of the board meeting will be made available on the company's website at https://vivantaindustries.com/disclosure/ as required under Regulation 46 of SEBI Listing Regulations.
The trading window for dealing in the company's securities remains closed for Directors, Officers, Key Managerial Personnel, and Designated Persons as defined under the company's Internal Code for Prohibition of Insider Trading. The closure will continue until the expiry of 48 hours after the declaration of Financial Results for the quarter ended 30th June 2026, in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015.
The disclosure is signed by Hemant Amrish Parikh, Managing Director (DIN: 00027820), and was digitally signed on 21st July 2026 at 13:20:12 IST.